Aquaron Acquisition (AQUNR) 10-Q14 Nov 242024 Q3 Quarterly reportFinancial data

Company Profile

Cover

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2024	Nov. 14, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Amendment Flag	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Entity Information [Line Items]
Entity Registrant Name	AQUARON ACQUISITION CORP.
Entity Central Index Key	0001861063
Entity File Number	001-41470
Entity Tax Identification Number	86-2760193
Entity Incorporation, State or Country Code	DE
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	No
Entity Shell Company	true
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Incorporation, Date of Incorporation	Mar. 11, 2021
Entity Contact Personnel [Line Items]
Entity Address, Address Line One	515 Madison Avenue
Entity Address, Address Line Two	8th Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10022
Entity Phone Fax Numbers [Line Items]
City Area Code	(646)
Local Phone Number	970 2181
Entity Listings [Line Items]
Entity Common Stock, Shares Outstanding		2,428,412
Units, each consisting of one share of Common Stock and one right to receive one-fifth (1/5) of a share of common stock
Entity Listings [Line Items]
Title of 12(b) Security	Units, each consisting of one share of Common Stock and one right to receive one-fifth (1/5) of a share of common stock
Trading Symbol	AQUNU
Security Exchange Name	NASDAQ
Common Stock, par value $0.0001
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock, par value $0.0001
Trading Symbol	AQU
Security Exchange Name	NASDAQ
Rights
Entity Listings [Line Items]
Title of 12(b) Security	Rights
Trading Symbol	AQUNR
Security Exchange Name	NASDAQ

Unaudited Condensed Balance She

Unaudited Condensed Balance Sheets - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current Assets
Cash	$ 109,650	$ 339
Prepaid income tax	144,736
Prepaid expenses	20,250	2,188
Total Current Assets	274,636	2,527
Noncurrent Assets
Deferred income tax asset		144,680
Investments held in Trust Account	9,109,815	31,960,267
Total Noncurrent Assets	9,109,815	32,104,947
Total Assets	9,384,451	32,107,474
Current Liabilities
Other payable – related party	138,665	97,052
Other payable - Huture	20,000
Accounts payable and accrued expenses	383,967	149,045
Franchise tax payable	22,300	18,495
Income tax payable		353,013
Excise tax payable	491,207	259,438
Total Current Liabilities	2,705,765	1,916,669
Deferred underwriting fee payable	2,525,896	2,525,896
Total Liabilities	5,231,661	4,442,565
Commitments and Contingencies (Note 6)
Common stock subject to possible redemption, $0.0001 par value; 10,000,000 shares authorized; 805,352 shares and 2,930,090 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	9,109,815	31,960,268
Stockholders’ Deficit
Common stock, $0.0001 par value; 10,000,000 shares authorized; 1,623,060 shares issued and outstanding (excluding 805,352 shares and 2,930,090 shares subject to possible redemption at September 30, 2024 and December 31, 2023, respectively)	163	163
Additional paid-in capital
Accumulated deficit	(4,957,188)	(4,295,522)
Total Stockholders’ Deficit	(4,957,025)	(4,295,359)
Total Liabilities, Redeemable Common Stock and Stockholders’ Deficit	9,384,451	32,107,474
Related Party
Current Liabilities
Promissory note – related party	849,626	549,626
Huture
Current Liabilities
Promissory note	40,000
Bestpath
Current Liabilities
Promissory note	$ 760,000	$ 490,000

Unaudited Condensed Balance S_2

Unaudited Condensed Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock subject to possible redemption, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized redemption value	10,000,000	10,000,000
Common stock, shares issued	805,352	2,930,090
Common stock, shares outstanding	805,352	2,930,090
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	10,000,000	10,000,000
Common stock, shares issued	1,623,060	1,623,060
Common stock, shares outstanding	1,623,060	1,623,060

Unaudited Condensed Statements

Unaudited Condensed Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
Unaudited Condensed Statements of Operations - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
General and administrative expenses	$ 345,648	$ 117,125	$ 545,126	$ 718,439
Franchise tax expenses	5,800	10,300	22,300	34,400
Loss from operations	(351,448)	(127,425)	(567,426)	(752,839)
Interest earned on investment held in Trust Account	116,923	548,881	752,116	1,569,987
Unrealized (loss) gain on investments held in Trust Account	(519)	(100,867)	37,433	133,387
Income before income taxes	(235,044)	320,589	222,123	950,535
Income taxes provision	(22,612)	(91,920)	(180,914)	(349,036)
Deferred income taxes benefit (provision)		24,596	(144,680)	114,673
Net income (loss)	$ (257,656)	$ 253,265	$ (103,471)	$ 716,172
Redeemable Common Stock
Basic weighted average shares outstanding (in Shares)	805,352	2,930,090	1,852,212	4,557,671
Diluted weighted average shares outstanding (in Shares)	805,352	2,930,090	1,852,212	4,557,671
Basic net income (loss) per share (in Dollars per share)	$ 0.06	$ 0.14	$ 0.05	$ 0.67
Diluted net income (loss) per share (in Dollars per share)	$ 0.06	$ 0.14	$ 0.05	$ 0.67
Non-Redeemable Common Stock
Basic weighted average shares outstanding (in Shares)	1,623,060	1,623,060	1,623,060	1,623,060
Diluted weighted average shares outstanding (in Shares)	1,623,060	1,623,060	1,623,060	1,623,060
Basic net income (loss) per share (in Dollars per share)	$ (0.19)	$ (0.09)	$ (0.12)	$ (1.44)
Diluted net income (loss) per share (in Dollars per share)	$ (0.19)	$ (0.09)	$ (0.12)	$ (1.44)

Unaudited Condensed Statement_2

Unaudited Condensed Statements of Changes in Stockholders’ Equity (Deficit) - USD ($)	Common Stock	Accumulated Deficit	Additional Paid-in Capital	Total
Balance at Dec. 31, 2022	$ 163	$ 159,672	$ 5,138,905	$ 5,298,740
Balance (in Shares) at Dec. 31, 2022	1,623,060
Accretion of common stock to redemption value			(4,135,212)	(4,135,212)
Net income		151,806		151,806
Balance at Mar. 31, 2023	$ 163	311,478	1,003,693	1,315,334
Balance (in Shares) at Mar. 31, 2023	1,623,060
Balance at Dec. 31, 2022	$ 163	159,672	5,138,905	5,298,740
Balance (in Shares) at Dec. 31, 2022	1,623,060
Net income				716,172
Balance at Sep. 30, 2023	$ 163	(3,878,654)		(3,878,491)
Balance (in Shares) at Sep. 30, 2023	1,623,060
Balance at Mar. 31, 2023	$ 163	311,478	1,003,693	1,315,334
Balance (in Shares) at Mar. 31, 2023	1,623,060
Accretion of common stock to redemption value		(3,819,853)	(1,003,693)	(4,823,546)
Excise tax liability		(259,438)		(259,438)
Net income		311,101		311,101
Balance at Jun. 30, 2023	$ 163	(3,456,712)		(3,456,549)
Balance (in Shares) at Jun. 30, 2023	1,623,060
Accretion of common stock to redemption value		(675,207)		(675,207)
Net income		253,265		253,265
Balance at Sep. 30, 2023	$ 163	(3,878,654)		(3,878,491)
Balance (in Shares) at Sep. 30, 2023	1,623,060
Balance at Dec. 31, 2023	$ 163	(4,295,522)		$ (4,295,359)
Balance (in Shares) at Dec. 31, 2023	1,623,060			1,623,060
Accretion of common stock to redemption value		(532,235)		$ (532,235)
Net income		98,814		98,814
Balance at Mar. 31, 2024	$ 163	(4,728,943)		(4,728,780)
Balance (in Shares) at Mar. 31, 2024	1,623,060
Balance at Dec. 31, 2023	$ 163	(4,295,522)		$ (4,295,359)
Balance (in Shares) at Dec. 31, 2023	1,623,060			1,623,060
Net income				$ (103,471)
Balance at Sep. 30, 2024	$ 163	(4,957,188)		$ (4,957,025)
Balance (in Shares) at Sep. 30, 2024	1,623,060			1,623,060
Balance at Mar. 31, 2024	$ 163	(4,728,943)		$ (4,728,780)
Balance (in Shares) at Mar. 31, 2024	1,623,060
Accretion of common stock to redemption value		402,213		402,213
Excise tax liability		(231,769)		(231,769)
Net income		55,371		55,371
Balance at Jun. 30, 2024	$ 163	(4,503,128)		(4,502,965)
Balance (in Shares) at Jun. 30, 2024	1,623,060
Accretion of common stock to redemption value		(196,404)		(196,404)
Net income		(257,656)		(257,656)
Balance at Sep. 30, 2024	$ 163	$ (4,957,188)		$ (4,957,025)
Balance (in Shares) at Sep. 30, 2024	1,623,060			1,623,060

Unaudited Condensed Statement_3

Unaudited Condensed Statements of Cash Flows - USD ($)	9 Months Ended
Unaudited Condensed Statements of Cash Flows - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net (loss) income	$ (103,471)	$ 716,172
Adjustments to reconcile net cash used in operating activities:
Interest earned on investment held in Trust Account	(752,116)	(1,569,987)
Unrealized gain on investments held in Trust Account	(37,433)	(133,387)
Deferred income tax provision (benefit)	144,680	(114,673)
Changes in operating assets and liabilities:
Other payable-related party	138,665
Other payable - Huture	20,000
Prepaid expenses	(18,062)	151,500
Accounts payable and accrued expenses	234,922	61,102
Franchise tax payable	3,805	13,493
Income tax payable	(497,749)	323,156
Net cash used in operating activities	(866,759)	(552,624)
Cash Flows from investing activities:
Cash deposited into Trust Account	(330,000)	(210,000)
Cash withdrawn from Trust Account to pay taxes	793,122	129,175
Cash withdrawn from Trust Account for public stockholder redemption	23,176,909	25,943,774
Net cash provided by investing activities	23,640,031	25,862,949
Cash Flows from financing activities:
Proceeds from promissory note- related party	202,948	370,000
Proceeds from promissory note- Bestpath	270,000	210,000
Proceeds from promissory note- Huture	40,000
Payment of public stockholder redemption	(23,176,909)	(25,943,774)
Net cash (used in) provided by financing activities	(22,663,961)	(25,363,774)
Net change in cash	109,311	(53,449)
Cash, beginning of the period	339	57,284
Cash, end of the period	109,650	3,835
Supplemental Disclosure of Non-cash Financing Activities
Accretion of common stock to redemption value	326,456	9,633,966
Excise tax payable charged against retained earnings	231,769	259,438
Promissory notes issued for the tax paid by Sponsor		79,780
Other payable due to related party converted to promissory note	$ 97,052	$ 99,846

Description of Organization and

Description of Organization and Business Operations	9 Months Ended
Description of Organization and Business Operations	Sep. 30, 2024
Description of Organization and Business Operations [Abstract]
Description of Organization and Business Operations	Note 1 — Description of Organization and Business Operations Aquaron Acquisition Corp. (“Aquaron” or the “Company”) is a newly organized blank check company incorporated as a Delaware corporation on March 11, 2021. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (the “Business Combination”). Although the Company is not limited to a particular industry or sector for purposes of consummating a Business Combination, the Company intends to focus on operating business in the new energy sector. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. As of September 30, 2024, the Company had not commenced any operations. All activities through September 30, 2024 are related to the Company’s formation and the initial public offering (“IPO” as defined below), and subsequent to the IPO, identifying a target company for an initial business combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income and investment gains from the proceeds derived from the IPO. The Company has selected December 31 as its fiscal year end. The Company’s sponsor is Aquaron Investments LLC (the “Sponsor”), a Delaware limited liability company. The registration statement for the Company’s IPO became effective on October 3, 2022. On October 6, 2022, the Company consummated the IPO of 5,000,000 units at an offering price of $10.00 per unit (the “Public Units’), generating gross proceeds of $50,000,000. Simultaneously with the IPO, the Company sold to its Sponsor 256,250 units at $10.00 per unit (the “Private Units”) in a private placement generating total gross proceeds of $2,562,500, which is described in Note 4. The Company granted the underwriter a 45-day option to purchase up to an additional 750,000 units at the IPO price to cover over-allotments, if any. On October 14, 2022, the underwriters partially exercised the over-allotment option to purchase 417,180 Units (“Over-Allotment Option Units”) at $10.00 per Unit generating total gross proceeds of $4,171,800. On October 14, 2022, simultaneously with the sale of the Over-Allotment Option Units, the Company consummated the Private Placement of an additional 12,515.40 Private Units generating gross proceeds of $125,154. A total of $54,984,377 of the net proceeds from the sale of the Units in the IPO (including the Over-Allotment Option Units) and the Private Placements on October 6, 2022 and October 14, 2022, were deposited in a trust account (the “Trust Account”) maintained by Continental Stock Transfer & Trust Company as a trustee and will be invested only in U.S. government treasury bills with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act of 1940, as amended (the “Investment Company Act”), and that invest only in direct U.S. government treasury obligations. These funds will not be released until the earlier of the completion of the initial Business Combination or the liquidation due to the Company’s failure to complete a Business Combination within the applicable period of time. The proceeds deposited in the Trust Account could become subject to the claims of the Company’s creditors, if any, which could have priority over the claims of the Company’s public stockholders. In addition, interest income earned on the funds in the Trust Account may be released to the Company to pay its income or other tax obligations. With these exceptions, expenses incurred by the Company may be paid prior to a business combination only from the net proceeds of the IPO and private placement not held in the Trust Account. Pursuant to Nasdaq listing rules, the Company’s initial Business Combination must occur with one or more target businesses having an aggregate fair market value equal to at least 80% of the value of the funds in the Trust account (excluding any deferred underwriting discounts and commissions and taxes payable on the income earned on the Trust Account), which the Company refers to as the 80% test, at the time of the execution of a definitive agreement for its initial Business Combination, although the Company may structure a Business Combination with one or more target businesses whose fair market value significantly exceeds 80% of the trust account balance. If the Company is no longer listed on Nasdaq, it will not be required to satisfy the 80% test. The Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. The Company will provide its holders of the outstanding Public Shares (the “Public Stockholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company solely in its discretion. The public stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.15 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its franchise and income tax obligations). If the Company seeks stockholder approval, a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the “Amended and Restated Certificate of Incorporation”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by law, or the Company decides to obtain stockholder approval for business or legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each public stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks stockholder approval in connection with a Business Combination, the Company’s Sponsor and any of the Company’s officers or directors that may hold Insider Shares (as defined in Note 5) (the “Initial Stockholders”) and Chardan have agreed (a) to vote their Insider Shares, Private Shares (as defined in Note 4) and any Public Shares purchased during or after the IPO in favor of approving a Business Combination and (b) not to convert any shares (including the Insider Shares) in connection with a stockholder vote to approve, or sell the shares to the Company in any tender offer in connection with, a proposed Business Combination. The Initial Stockholders and Chardan have agreed (a) to waive their redemption rights with respect to the Insider Shares, Private Shares and Public Shares held by them in connection with the completion of a Business Combination and (b) not to propose, or vote in favor of, an amendment to the Amended and Restated Certificate of Incorporation that would affect the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the public stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment. Initially, the Company had until 9 months from the closing of the IPO to consummate a Business Combination. In addition, if the Company anticipates that it may not be able to consummate initial business combination within 9 months, the Company’s insiders or their affiliates may, but are not obligated to, extend the period of time to consummate a business combination two times by an additional three months each time (for a total of 12 or 15 months to complete a business combination) (the “Combination Period”). In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliate or designees must deposit into the Trust Account $750,000 ($0.15 per Public Share or an aggregate of $1,500,000) on or prior to the date of the applicable deadline. Merger Agreement On March 23, 2023, the Company entered into an Agreement and Plan of Merger (the “ Bestpath Merger Agreement Bestpath Reorganization On July 12, 2024, Aquaron entered into an Agreement and Plan of Merger (as amended from time to time, the “ Agreement Huture PubCo Merger Sub 1 Merger Sub 2 Acquisition Entity Acquisition Entities Pursuant to the Agreement and subject to the terms and conditions set forth therein, (i) Merger Sub 1 will merge with and into Huture (the “ Initial Merger SPAC Merger Mergers The Mergers implies a current equity value of Huture at $1.0 billion prior to the closing of the Mergers (the “ Closing PubCo Ordinary Shares Extension Meetings On June 28, 2023, the Company held a special meeting of stockholders, at which the Company’s stockholders approved (i) an amendment to the Company’s amended and restated certificate of incorporation (the “Extension Amendment”) and (ii) an amendment (the “Trust Amendment”) to the Investment Management Trust Agreement, dated October 3, 2022, by and between the Company and Continental Stock Transfer & Trust Company to allow the Company to extend the Business Combination Period for a period of three months from July 6, 2023 to October 6, 2023, plus an option for the Company to further extend such date to January 6, 2024, and then on a monthly basis up to four times from January 6, 2024 to May 6, 2024 by depositing into the trust account $70,000 for each one-month extension. In connection with the stockholders’ vote at the special meeting, an aggregate of 2,487,090 shares with redemption value of approximately $25,943,773 (or $10.43 per share) of the Company’s common stock were tendered for redemption. On June 29, 2023, October 4, 2023 and December 29, 2023, Bestpath (Shanghai) IoT Technology Co., Ltd. (“Bestpath”, see Merger Agreement below) provided loans by depositing in the Trust Account $210,000, $210,000 and $70,000 (totaling $490,000), respectively, and from January 2024 to April 2024, Bestpath provided loans of $70,000 each month to the Company to fund the amount required to extend the Business Combination Period to May 6, 2024. On May 2, 2024, June 4, 2024, and July 8, 2024, Bestpath provided a loan of $20,000 each time to the Company to fund the amount required to extend the Business Combination Period to August 6, 2024. In return, the Company issued an unsecured promissory note of $70,000 each time from January 2024 to April 2024 and $20,000 each time from May 2024 to July 2024 to Bestpath in exchange for Bestpath depositing such amount into the Company’s trust account in order to extend the amount of time it has available to complete a business combination. On August 6, 2024, September 4, 2024, October 2, 2024 and November 5, 2024, the Company issued an unsecured promissory note of $20,000 each time to Huture in exchange for the latter depositing such amount into the Company’s trust account in order to extend the Business Combination Period to December 6, 2024. All these promissory notes are unsecured, interest-free and payable on the earlier of: 1) the date on which the Company consummates an initial business combination, or 2) the date of the merger agreement with Huture is terminated, or 3) the outside closing date defined in the Merger Agreement. On April 30, 2024, the Company held an annual stockholder meeting, at which the Company’s stockholders approved (i) an amendment to the Company’s amended and restated certificate of incorporation and (ii) an amendment to the Investment Management Trust Agreement, dated October 3, 2022 and amended on June 28, 2023, by and between the Company and Continental Stock Transfer & Trust Company to allow the Company to extend the Business Combination Period for up to twelve months on a monthly basis from May 6, 2024 to May 6, 2025 by depositing into the trust account $20,000 for each one-month extension. In connection with the stockholders’ vote at the annual meeting, an aggregate of 2,124,738 shares with redemption value of $23,176,909 (or approximately $10.91 per share) of the Company’s common stock were tendered for redemption. If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest (which interest shall be net of taxes payable, and less up to $50,000 of interest to pay dissolution expenses) divided by the number of then outstanding Public Shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. The Sponsor and Chardan have agreed to waive their liquidation rights with respect to the Insider Shares and Private Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsor or Chardan acquires Public Shares in or after the IPO, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than $10.15. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below $10.15 per Public Share, except as to any claims by a third party who executed a valid and enforceable agreement with the Company waiving any right, title, interest or claim of any kind they may have in or to any monies held in the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of IPO against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third party claims. Going Concern Consideration As of September 30, 2024, the Company had $109,650 in cash and working capital deficit of $2,431,129. The Company’s liquidity needs prior to the consummation of the IPO had been satisfied through a payment from the Sponsor of $25,000 for the Insider Shares and the loan under an unsecured promissory note from the Sponsor of $300,000 which was repaid in October 2022. During 2023, the Sponsor provided loans totaling $449,780 (excluding $99,846 converted from amount due to related party), to be used, in part, for transaction costs related to the Business Combination (see Note 5). On January 4, 2024 and March 30, 2024, the Company issued an unsecured promissory note to the Sponsor in the aggregate principal amount of $200,000 (including the conversion of $97,052 which was outstanding balance as of December 31, 2023 due to Sponsor) and $100,000, respectively, to be used, in part, for transaction costs related to the Business Combination. On June 29, 2023, October 4, 2023 and December 29, 2023, Bestpath deposited into the Trust Account $210,000, $210,000 and $70,000 (totaling $490,000), respectively, and from January 2024 to April 2024, Bestpath provided loans of $70,000 each month to the Company to fund the amount required to extend the Business Combination Period to May 6, 2024. On May 2, 2024, June 4, 2024 and July 8, 2024, Bestpath provided a loan of $20,000 each time to the Company to fund the amount required to extend the Business Combination Period to August 6, 2024. From August to November 2024, Huture provided a loan of $20,000 each time to the Company to fund the amount required to extend the Business Combination Period to December 6, 2024. The Company has now until December 6, 2024 to consummate a Business Combination. It is uncertain that the Company will be able to consummate a Business Combination by this time. If a Business Combination is not consummated by this date, there will be a mandatory liquidation and subsequent dissolution. The Company expects to continue to incur significant professional costs to remain as a publicly traded company and to incur significant transaction costs in pursuit of the consummation of a Business Combination. The Company may need to obtain additional financing either to complete its Business Combination or because it becomes obligated to redeem a significant number of public shares upon consummation of its Business Combination, in which case the Company may issue additional securities or incur debt in connection with such Business Combination. Subject to compliance with applicable securities laws, the Company would only complete such financing simultaneously with the completion of our Business Combination. If the Company is unable to complete its Business Combination because it does not have sufficient funds available, it will be forced to cease operations and liquidate the Trust Account. In addition, following the Business Combination, if cash on hand is insufficient, the Company may need to obtain additional financing in order to meet its obligations. In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern”, management has determined that if the Company is unable to complete a Business Combination by December 6, 2024 (unless the Company extends the time to complete a Business Combination), then the Company will cease all operations except for the purpose of liquidating. The date for liquidation and subsequent dissolution raises substantial doubt about the Company’s ability to continue as a going concern. The financial statement does not include any adjustments that might result from the outcome of this uncertainty. Risks and Uncertainties Management has evaluated the impact of persistent inflation and rising interest rates, financial market instability, including the recent bank failures, the lingering effects of the COVID-19 pandemic and certain geopolitical events, including the conflict in Ukraine and the surrounding region, as well as delisting issue for non-compliance with Nasdaq Listing Rules, and has concluded that while it is reasonably possible that the risks and uncertainties related to or resulting from these events could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The unaudited condensed financial statements do not include any adjustments that might result from the outcome of these risks and uncertainties. On August 16, 2022, the Inflation Reduction Act of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases (including redemptions) of stock by publicly traded domestic (i.e., U.S.) corporations and certain domestic subsidiaries of publicly traded foreign corporations. The excise tax is imposed on the repurchasing corporation itself, not its shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the “Treasury”) has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax. The IR Act applies only to repurchases that occur after December 31, 2022. Any redemption or other repurchase that occurs after December 31, 2022, in connection with a Business Combination, extension vote or otherwise, may be subject to the excise tax. Whether and to what extent the Company would be subject to the excise tax in connection with a Business Combination, extension vote or otherwise would depend on a number of factors, including (i) the fair market value of the redemptions and repurchases in connection with the Business Combination, extension or otherwise, (ii) the structure of a Business Combination, (iii) the nature and amount of any “PIPE” or other equity issuances in connection with a Business Combination (or otherwise issued not in connection with a Business Combination but issued within the same taxable year of a Business Combination) and (iv) the content of regulations and other guidance from the Treasury. In addition, because the excise tax would be payable by the Company and not by the redeeming holder, the mechanics of any required payment of the excise tax have not been determined. The foregoing could cause a reduction in the cash available on hand to complete a Business Combination and in the Company’s ability to complete a Business Combination. At this time, it has been determined that the IR Act tax provisions have an impact to the Company’s fiscal 2023 and fiscal 2024 tax provision as there were redemptions by the public stockholders in June 2023 and May 2024; as a result, the Company recorded $259,438 and $231,769 excise tax liability, respectively. Total excise tax liability of $491,207 was outstanding as of September 30, 2024. During the second quarter 2024, the Internal Revenue Service issued final regulations with respect to the timing and payment of the Excise Tax. Pursuant to those regulations, the Company would need to file a return and remit payment for any liability incurred during the period from January 1, 2023 to December 31, 2023 on or before October 31, 2024. As of November 14, 2024, the Company did not file a tax return and remit the payment for the exercise tax payable. The Company will continue to monitor for updates to the Company’s business along with guidance issued with respect to the IR Act to determine whether any adjustments are needed to the Company’s excise tax liability in future periods.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2024
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 — Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the SEC. Accordingly, they include all of the information and footnotes required by GAAP. In the opinion of management, all adjustments (consisting of normal accruals) considered for a fair presentation have been included. The interim results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected through December 31, 2024 or for any future periods. These financial statements should be read in conjunction with the Company’s 2023 Annual Report on Form 10-K as filed with the SEC on May 3, 2024. Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Use of Estimates In preparing these unaudited financial statements in conformity with U.S. GAAP, the Company’s management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $109,650 and $339 in cash and none Investments Held in Trust Account The Company’s portfolio of investments held in the Trust Account is comprised of investments in money market funds that invest in U.S. government securities. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in interest earned on marketable securities held in Trust Account in the accompanying statements of operations. The estimated fair value of investments held in the Trust Account is determined using available market information. As of September 30, 2024 and December 31, 2023, the Trust Account had balance of $9,109,815 and $31,960,267, respectively. The interest earned from the Trust Account totaled $789,549 and $1,703,374 for the nine months ended September 30, 2024 and 2023, respectively, which were fully reinvested into the Trust Account as earned and unrealized gain on investments and therefore presented as an adjustment to the operating activities in the Statements of Cash Flows. Income Taxes The Company accounts for income taxes under ASC 740, “Income Taxes.” ASC 740, Income Taxes, requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the unaudited condensed financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. The Company’s effective tax rate was (9.62)% and 26.09% for the three months ended September 30, 2024 and 2023, respectively, and 146.54% and 24.66% for the nine months ended September 30, 2024 and 2023, respectively. The effective tax rate differs from the statutory tax rate of 21% for the three and nine months ended September 30, 2024 and 2023, due to non-deductible M&A costs and the change of valuation allowance on the deferred tax assets. After consideration of all of the information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance. The change in the valuation allowance was $28,258 and $233,626 for the three and nine months ended September 30, 2024, respectively. The Company’s net deferred tax assets are as follows: September 30, December 31, 2024 2023 Deferred tax asset (liability) Startup/Organization Expenses $ 243,409 $ 174,157 Amortization of startup cost (5,069 ) (2,897 ) Unrealized gain on investments held in Trust Account (7,861 ) (29,727 ) Total deferred tax asset (liability) 230,479 141,533 Valuation allowance (230,479 ) 3,147 Deferred tax asset, net of allowance $ — $ 144,680 ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. While ASC 740 identifies usage of an effective annual tax rate for purposes of an interim provision, it does allow for estimating individual elements in the current period if they are significant, unusual or infrequent. Computing the effective tax rate for the Company is complicated due to the potential impact of the timing of any Business Combination expenses and the actual interest income that will be recognized during the year. The Company has taken a position as to the calculation of income tax expense in a current period based on ASC 740-270-25-3 which states, “If an entity is unable to estimate a part of its ordinary income (or loss) or the related tax (benefit) but is otherwise able to make a reasonable estimate, the tax (or benefit) applicable to the item that cannot be estimated shall be reported in the interim period in which the item is reported.” The Company believes its calculation to be a reliable estimate and allows it to properly take into account the usual elements that can impact its annualized book income and its impact on the effective tax rate. As such, the Company is computing its taxable income (loss) and associated income tax provision based on actual results through September 30, 2024. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of September 30, 2024. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has identified the United States as its only “major” tax jurisdiction. The Company may be subject to potential examination by federal and state taxing authorities in the areas of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. Net Income (Loss) Per Share The Company complies with accounting and disclosure requirements of FASB ASC 260, Earnings Per Share. The statements of operations include a presentation of income (loss) per redeemable share and income (loss) per non-redeemable share following the two-class method of income per share. In order to determine the net income (loss) attributable to both the redeemable shares and non-redeemable shares, the Company first considered the undistributed income (loss) allocable to both the redeemable shares and non-redeemable shares and the undistributed income (loss) is calculated using the total net loss less any dividends paid. The Company then allocated the undistributed income (loss) ratably based on the weighted average number of shares outstanding between the redeemable and non-redeemable shares. Any remeasurement of the accretion to redemption value of the common shares subject to possible redemption was considered to be dividends paid to the public shareholders. As of September 30, 2024 and 2023, the Company did not have any dilutive securities and other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted loss per share is the same as basic loss per share for the period presented. The net income (loss) per share presented in the statements of operations is based on the following: Three Months Ended Nine Months Ended 2024 2023 2024 2023 Net income (loss) $ (257,656 ) $ 253,265 $ (103,471 ) $ 716,172 Accretion of common stock to redemption value (1) (196,404 ) (675,207 ) (326,456 ) (9,633,966 ) Net loss including accretion of common stock to redemption value $ (454,060 ) $ (421,942 ) $ (429,927 ) $ (8,917,794 ) Three Months Ended Three Months Ended Redeemable Non- redeemable Redeemable Non- redeemable Basic and diluted net income (loss) per common stock Numerator: Allocation of net loss $ (150,583 ) $ (303,477 ) $ (271,532 ) $ (150,410 ) Accretion of common stock to redemption value (1) 196,404 — 675,207 Allocation of net income (loss) $ 45,821 $ (303,477 ) $ 403,675 $ (150,410 ) Denominator: Basic and diluted weighted average shares outstanding 805,352 1,623,060 2,930,090 1,623,060 Basic and diluted net income (loss) per common stock $ 0.06 $ (0.19 ) $ 0.14 $ (0.09 ) Nine Months Ended Nine Months Ended Redeemable Non- redeemable Redeemable Non- redeemable Basic and diluted net income (loss) per common stock Numerator: Allocation of net loss $ (229,138 ) $ (200,789 ) $ (6,575,981 ) $ (2,341,813 ) Accretion of common stock to redemption value (1) 326,456 — 9,633,966 — Allocation of net income (loss) $ 97,318 $ (200,789 ) $ 3,057,985 $ (2,341,813 ) Denominator: Basic and diluted weighted average shares outstanding 1,852,212 1,623,060 4,557,671 1,623,060 Basic and diluted net income (loss) per common stock $ 0.05 $ (0.12 ) $ 0.67 $ (1.44 ) (1) Accretion amount includes fees deposited into the Trust Account to extend the time for the Company to complete the Business Combination and franchise and income taxes paid out of the Trust Account. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. As of September 30, 2024 and December 31, 2023, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 825, “Financial Instruments,” approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature. Common Stock Subject to Possible Redemption The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable common stock (including common stock that feature redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet. The Company has made a policy election in accordance with ASC 480-10-S99-3A and recognizes changes in redemption value in accumulated deficit over an expected 12-month period leading up to a Business Combination. As of September 30, 2024, the Company recorded $326,456 accretion of common stock to redemption value. At September 30, 2024, the amount of common stock subject to possible redemption reflected in the balance sheet are reconciled in the following table: Gross proceeds $ 54,171,800 Less: Proceeds allocated to public rights (6,446,444 ) Allocation of offering costs related to redeemable shares (3,714,253 ) Plus: Accretion of carrying value to redemption value 3,560,360 Common stock subject to possible redemption- December 31, 2022 47,571,463 Plus: Accretion of carrying value to redemption value – for the year ended December 31, 2023 10,332,578 Redeemed common stock payable to public stockholders (25,943,773 ) Common stock subject to possible redemption- December 31, 2023 31,960,268 Plus: Accretion of carrying value to redemption value - nine months ended September 30, 2024 326,456 Redeemed common stock payable to public stockholders (23,176,909 ) Common stock subject to possible redemption- September 30, 2024 $ 9,109,815 Convertible Promissory Note The Company elects an early adoption of the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) and accounts for its convertible promissory notes as debt (liability) on the balance sheet. The Company’s assessment of the embedded conversion feature (see Note 5 - Related Party Transactions) considers the derivative scope exception guidance under ASC 815 pertaining to equity classification of contracts in an entity’s own equity. The conversion feature of these promissory notes meets the definition of a derivative instrument. However, bifurcation of conversion feature from the debt host is not required because the conversion feature meets ASC 815 scope exception, as the promissory notes are convertible in shares of the Company’s common stock which is considered indexed to the Company’s own stock and classified in stockholders’ equity. Recent Accounting Pronouncements In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” (“ASU 2023-09”). This ASU requires that public business entities must annually “(1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income or loss by the applicable statutory income tax rate).” A public entity should apply the amendments in ASU 2023-09 prospectively to all annual periods beginning after December 15, 2024. The Company is currently assessing the impact, if any, that ASU 2023-09 would have on its financial position, results of operations or cash flows. Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.

Initial Public Offering

Initial Public Offering	9 Months Ended
Initial Public Offering	Sep. 30, 2024
Class of Stock Disclosures [Abstract]
Initial Public Offering	Note 3 — Initial Public Offering On October 6, 2022, the Company sold 5,000,000 Units at a price of $10.00 per Unit, generating gross proceeds of $50,000,000 related to its IPO. The Company granted the underwriter a 45-day option to purchase up to an additional 750,000 Units at the IPO price to cover over-allotments, if any. On October 14, 2022, the underwriters partially exercised the over-allotment option to purchase 417,180 Over-Allotment Option Units at $10.00 per Unit generating total gross proceeds of $4,171,800. Each Unit consists of one share of common stock and one right (“Public Right”). Each Public Right will convert into one-fifth (1/5) of one share of common stock upon the consummation of a Business Combination. All of the 5,417,180 Public Shares sold as part of the Public Units in the IPO (including the Over-Allotment Option Units) contain a redemption feature which allows for the redemption of such Public Shares if there is a stockholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company’s amended and restated certificate of incorporation, or in connection with the Company’s liquidation. In accordance with the SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require common stock subject to redemption to be classified outside of permanent equity. The Company’s redeemable common stock is subject to SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99. If it is probable that the equity instrument will become redeemable, the Company has the option to either accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or to recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. The Company has made a policy election in accordance with ASC 480-10-S99-3A and recognizes changes in redemption value in additional paid-in capital (or accumulated deficit in the absence of additional paid-in capital) over an expected 12-month period leading up to a Business Combination.

Private Placement

Private Placement	9 Months Ended
Private Placement	Sep. 30, 2024
Class of Stock Disclosures [Abstract]
Private Placement	Note 4 — Private Placement Simultaneously with the closing of the IPO on October 6, 2022, the Sponsor purchased an aggregate of 256,250 Private Units at a price of $10.00 per Private Unit for an aggregate purchase price of $2,562,500 in a private placement. Each Private Unit will consist of one share of common stock (“Private Share”) and one right (“Private Right”). On October 14, 2022, simultaneously with the sale of the Over-Allotment Option Units, the Company consummated the sale of an additional 12,515.40 Private Units generating gross proceeds of $125,154. Each Private Right will convert into one-fifth (1/5) of one share of common stock upon the consummation of a Business Combination. The net proceeds from the Private Units were added to the proceeds from the IPO to be held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Units will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law), and the Private Units and all underlying securities will expire worthless.

Related Party Transactions

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2024
Related Party Transactions [Abstract]
Related Party Transactions	Note 5 — Related Party Transactions Insider Shares On April 1, 2021, the Company issued 1,437,500 shares of common stock to the Initial Stockholders (the “Insider Shares”) for an aggregated consideration of $25,000, The Insider Shares include an aggregate of up to 187,500 shares subject to forfeiture by the Initial Stockholders to the extent that the underwriters’ over-allotment is not exercised in full, so that the Initial Stockholders will collectively own 20% of the Company’s issued and outstanding shares after the IPO (assuming the Initial Stockholders do not purchase any Public Shares in the IPO and excluding the Private Units). As a result of the partial exercise of the underwriters’ over-allotment option which was closed on October 14, 2022, the Company cancelled an aggregate of 83,205 Insider Shares. The Initial Stockholders have agreed, subject to certain limited exceptions, not to transfer, assign or sell any of their Insider Shares until, with respect to 50% of the Insider Shares, the earlier of nine months after the consummation of a Business Combination and the date on which the closing price of the common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period commencing after a Business Combination and, with respect to the remaining 50% of the Insider Shares, until the nine months after the consummation of a Business Combination, or earlier, in either case, if, subsequent to a Business Combination, the Company completes a liquidation, merger, stock exchange or other similar transaction which results in all of the Company’s stockholders having the right to exchange their shares of common stock for cash, securities or other property. Promissory Note — Related Party On February 8, 2023, February 23, 2023 and March 31, 2023, the Sponsor provided the Company a loan of $100,000 (“Promissory Note 1”), $140,000 (“Promissory Note 2”) and $130,000 (“Promissory Note 3”), respectively, to be used, in part, for transaction costs related to the Business Combination. On June 26, 2023, the Sponsor provided a loan of $179,626 (“Promissory Note 4”) including the conversion of $99,846 due to related party (see below) for working capital purposes. The Sponsor has the right to convert these promissory notes into shares of the Company common stock at a fixed price of $10.00 per share at any time when these promissory notes remain outstanding. On January 4, 2024 and March 30, 2024, the Company issued an unsecured promissory note to the Sponsor in the aggregate principal amount of $200,000 (including the conversion of $97,052 which was outstanding balance as of December 31, 2023 due to Sponsor) (“Promissory Note 5”) and $100,000 (“Promissory Note 6”), respectively, to be used, in part, for transaction costs related to the Business Combination. The Sponsor has the right to convert the promissory note into shares of the Company common stock at a price of approximately $8.33 per share at any time when these promissory notes remain outstanding. Each Promissory Note is unsecured, interest-free and payable on the earlier of: 1) the date on which the Company consummates an initial business combination, or 2) the date the Company liquidates if a business combination is not consummated. As of September 30, 2024 and December 31, 2023, $849,626 and $549,626 were outstanding, respectively, under all the Promissory Notes. Due to Related Party The Company received additional funds from the Sponsor at the closing of IPO to finance transaction costs in connection with searching for a target business. On June 26, 2023, $99,846 outstanding amount due to related party was converted to Promissory Note 4 (see above). Additionally, the Sponsor provided work capital and paid certain expenses on behalf of the Company. As of September 30, 2024 and December 31, 2023, the amount due to related party was $138,665 and $97,052, respectively; of which $97,052 was subsequently converted to Promissory Note 5 (see above). Promissory Note — Bestpath On June 29, 2023 and October 3, 2023, Bestpath provided a loan of $210,000 each time to the Company. On December 29, 2023, the Company received the advance of $70,000 from Bestpath for the promissory note issued on January 3, 2024. On February 2, 2024, March 1, 2024 and April 8, 2024, the Company issued an unsecured promissory note of $70,000 each time to Bestpath in exchange for Bestpath depositing such amount into the Company’s trust account in order to extend the amount of time it has available to complete a business combination. On May 2, 2024, June 4, 2024 and July 8, 2024, the Company issued an unsecured promissory note of $20,000 each time to Bestpath in exchange for Bestpath depositing such amount into the Company’s trust account in order to extend the amount of time it has available to complete a business combination. These funds were amounts required to extend the Business Combination Period to August 6, 2024. All Bestpath promissory notes are unsecured, interest-free and payable on the earlier of: 1) the date on which the Company consummates an initial business combination, or 2) the date of the merger agreement with Bestpath is terminated, or 3) the outside closing date defined in the merger agreement. Bestpath has the right to convert the promissory notes into shares of the Company common stock at approximately $8.33 per share. As of September 30, 2024 and December 31, 2023, $760,000 and $490,000 were outstanding respectively, under the Bestpath promissory notes. Promissory Note — Huture On August 2, 2024, August 30, 2024 and September 30, 2024, Huture deposited into trust account of $20,000 each time in order to extend the Business Combination Period to November 6, 2024. In exchanging these deposits, the Company issued the unsecured promissory notes to Huture. The promissory notes are unsecured, interest-free and payable on the earlier of: 1) the date on which the Company consummates an initial business combination, or 2) the date of the merger agreement with Huture is terminated, or 3) the outside closing date defined in the Merger Agreement. In addition, Huture has the right to convert the promissory note into shares of the Company common stock at a price of approximately $8.33 per share. As of September 30, 2024 and December 31, 2023, $40,000 and $0 were outstanding respectively, under the Huture promissory notes. On October 2, 2024, the Company issued an unsecured promissory note of $20,000 to Huture in exchange for Huture depositing such amount into the Company’s trust account on September 30, 2024.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2024
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 6 — Commitments and Contingencies Registration Rights The holders of the Founder Shares, Private Units (and all underlying securities), and any shares that may be issued upon conversion of working capital loans will be entitled to registration rights pursuant to a registration rights agreement signed on the effective date of IPO. The holders of the majority of these securities are entitled to make up to three demands that the Company register such securities. The holders of the majority of the Founder Shares can elect to exercise these registration rights at any time commencing three months prior to the date on which the Founder Shares are to be released from escrow. The holders of a majority of the Private Units and units issued in payment of working capital loans made to the Company can elect to exercise these registration rights at any time commencing on the date that the Company consummates a Business Combination. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Underwriting Agreement The Company has granted the underwriters a 45-day option from the date of the prospectus to purchase up to 750,000 additional Units to cover over-allotments, if any, at the IPO price less the underwriting discounts and commissions. The underwriters were paid a cash underwriting discount of $812,577. In addition, the underwriters are entitled to a deferred fee of 3.5% of the gross proceeds of the IPO, or $1,896,013, which will be paid upon the closing of a Business Combination from the amounts held in the Trust Account, subject to the terms of the underwriting agreement. The underwriters are also entitled to 0.75% of the gross proceeds of the IPO in the form of common stock of the Company at a price of $10.00 per share, to be issued if the Company closes a business combination. In addition, the Company has agreed to issue to Chardan and/or its designees 50,000 Private Units as a deferred underwriting commission if the Company closes a business combination. If a business combination is not consummated, such Private Units will not be issued and Chardan’s (and/or its designees) right to receive them will be forfeited. Unit Purchase Option On October 6, 2022, the Company sold to Chardan (and/or its designees), for $100, an option (“UPO”) to purchase 97,509 Units (including the over-allotment option units). The UPO is exercisable at any time, in whole or in part, between the close of the Business Combination and fifth anniversary of the date of the Business Combination at a price per Unit equal to $11.50 (or 115% of the volume weighted average trading price of the ordinary shares during the 20 trading day period starting on the trading day immediately prior to consummation of an initial Business Combination). The option and the underlying securities that may be issued upon exercise of the option, have been deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to Rule 5110(e)(1) of FINRA’s NASDAQ Conduct Rules. Additionally, the option may not be sold, transferred, assigned, pledged or hypothecated for a one-year period (including the foregoing 180-day period) following the date of IPO except to any underwriter and selected dealer participating in the IPO and their bona fide officers or partners.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
Stockholders' Equity	Sep. 30, 2024
Stockholders' Equity [Abstract]
Stockholders' Equity	Note 7 — Stockholders’ Equity Common Stock Rights If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of rights will not receive any of such funds with respect to their rights, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such rights, and the rights will expire worthless. Further, there are no contractual penalties for failure to deliver securities to the holders of the rights upon consummation of a Business Combination. Additionally, in no event will the Company be required to net cash settle the rights. Accordingly, the rights may expire worthless.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
Fair Value Measurements	Sep. 30, 2024
Fair Value Measurements [Abstract]
Fair Value Measurements	Note 8 — Fair Value Measurements The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. Level 3: Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. The following tables present information about the Company’s assets that are measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023 and indicate the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value. September 30, Quoted Significant Significant Assets Marketable securities held in the Trust Account 9,109,815 9,109,815 — — December 31, Quoted Significant Significant Assets Marketable securities held in the Trust Account 31,960,267 31,960,267 — —

Subsequent Events

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	Note 9 — Subsequent Events The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based on the review, management identified the following subsequent events that would have required disclosure in the condensed financial statements. On November 5, 2024, the Company issued an unsecured promissory note of $20,000 to Huture in exchange for Huture depositing such amount into the Company’s trust account in order to extend the Business Combination Period to December 6, 2024. The promissory notes are unsecured, interest-free and payable on the earlier of: 1) the date on which the Company consummates an initial business combination, or 2) the date of the merger agreement with Huture is terminated, or 3) the outside closing date defined in the Merger Agreement. In addition, Huture has the right to convert the promissory note into shares of the Company common stock at a price of approximately $8.33 per share. On November 4, 2024, the Company received a decision letter from the Nasdaq Hearings Panel (“ Panel Nasdaq Rule Minimum Public Holders Rule

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended						9 Months Ended
Pay vs Performance Disclosure - USD ($)	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (257,656)	$ 55,371	$ 98,814	$ 253,265	$ 311,101	$ 151,806	$ (103,471)	$ 716,172

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
Accounting Policies, by Policy (Policies)	Sep. 30, 2024
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the SEC. Accordingly, they include all of the information and footnotes required by GAAP. In the opinion of management, all adjustments (consisting of normal accruals) considered for a fair presentation have been included. The interim results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected through December 31, 2024 or for any future periods. These financial statements should be read in conjunction with the Company’s 2023 Annual Report on Form 10-K as filed with the SEC on May 3, 2024.
Emerging Growth Company	Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates	Use of Estimates In preparing these unaudited financial statements in conformity with U.S. GAAP, the Company’s management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $109,650 and $339 in cash and none
Investments Held in Trust Account	Investments Held in Trust Account The Company’s portfolio of investments held in the Trust Account is comprised of investments in money market funds that invest in U.S. government securities. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in interest earned on marketable securities held in Trust Account in the accompanying statements of operations. The estimated fair value of investments held in the Trust Account is determined using available market information. As of September 30, 2024 and December 31, 2023, the Trust Account had balance of $9,109,815 and $31,960,267, respectively. The interest earned from the Trust Account totaled $789,549 and $1,703,374 for the nine months ended September 30, 2024 and 2023, respectively, which were fully reinvested into the Trust Account as earned and unrealized gain on investments and therefore presented as an adjustment to the operating activities in the Statements of Cash Flows.
Income Taxes	Income Taxes The Company accounts for income taxes under ASC 740, “Income Taxes.” ASC 740, Income Taxes, requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the unaudited condensed financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. The Company’s effective tax rate was (9.62)% and 26.09% for the three months ended September 30, 2024 and 2023, respectively, and 146.54% and 24.66% for the nine months ended September 30, 2024 and 2023, respectively. The effective tax rate differs from the statutory tax rate of 21% for the three and nine months ended September 30, 2024 and 2023, due to non-deductible M&A costs and the change of valuation allowance on the deferred tax assets. After consideration of all of the information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance. The change in the valuation allowance was $28,258 and $233,626 for the three and nine months ended September 30, 2024, respectively. The Company’s net deferred tax assets are as follows: September 30, December 31, 2024 2023 Deferred tax asset (liability) Startup/Organization Expenses $ 243,409 $ 174,157 Amortization of startup cost (5,069 ) (2,897 ) Unrealized gain on investments held in Trust Account (7,861 ) (29,727 ) Total deferred tax asset (liability) 230,479 141,533 Valuation allowance (230,479 ) 3,147 Deferred tax asset, net of allowance $ — $ 144,680 ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. While ASC 740 identifies usage of an effective annual tax rate for purposes of an interim provision, it does allow for estimating individual elements in the current period if they are significant, unusual or infrequent. Computing the effective tax rate for the Company is complicated due to the potential impact of the timing of any Business Combination expenses and the actual interest income that will be recognized during the year. The Company has taken a position as to the calculation of income tax expense in a current period based on ASC 740-270-25-3 which states, “If an entity is unable to estimate a part of its ordinary income (or loss) or the related tax (benefit) but is otherwise able to make a reasonable estimate, the tax (or benefit) applicable to the item that cannot be estimated shall be reported in the interim period in which the item is reported.” The Company believes its calculation to be a reliable estimate and allows it to properly take into account the usual elements that can impact its annualized book income and its impact on the effective tax rate. As such, the Company is computing its taxable income (loss) and associated income tax provision based on actual results through September 30, 2024. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of September 30, 2024. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has identified the United States as its only “major” tax jurisdiction. The Company may be subject to potential examination by federal and state taxing authorities in the areas of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.
Net Income (Loss) Per Share	Net Income (Loss) Per Share The Company complies with accounting and disclosure requirements of FASB ASC 260, Earnings Per Share. The statements of operations include a presentation of income (loss) per redeemable share and income (loss) per non-redeemable share following the two-class method of income per share. In order to determine the net income (loss) attributable to both the redeemable shares and non-redeemable shares, the Company first considered the undistributed income (loss) allocable to both the redeemable shares and non-redeemable shares and the undistributed income (loss) is calculated using the total net loss less any dividends paid. The Company then allocated the undistributed income (loss) ratably based on the weighted average number of shares outstanding between the redeemable and non-redeemable shares. Any remeasurement of the accretion to redemption value of the common shares subject to possible redemption was considered to be dividends paid to the public shareholders. As of September 30, 2024 and 2023, the Company did not have any dilutive securities and other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted loss per share is the same as basic loss per share for the period presented. The net income (loss) per share presented in the statements of operations is based on the following: Three Months Ended Nine Months Ended 2024 2023 2024 2023 Net income (loss) $ (257,656 ) $ 253,265 $ (103,471 ) $ 716,172 Accretion of common stock to redemption value (1) (196,404 ) (675,207 ) (326,456 ) (9,633,966 ) Net loss including accretion of common stock to redemption value $ (454,060 ) $ (421,942 ) $ (429,927 ) $ (8,917,794 ) Three Months Ended Three Months Ended Redeemable Non- redeemable Redeemable Non- redeemable Basic and diluted net income (loss) per common stock Numerator: Allocation of net loss $ (150,583 ) $ (303,477 ) $ (271,532 ) $ (150,410 ) Accretion of common stock to redemption value (1) 196,404 — 675,207 Allocation of net income (loss) $ 45,821 $ (303,477 ) $ 403,675 $ (150,410 ) Denominator: Basic and diluted weighted average shares outstanding 805,352 1,623,060 2,930,090 1,623,060 Basic and diluted net income (loss) per common stock $ 0.06 $ (0.19 ) $ 0.14 $ (0.09 ) Nine Months Ended Nine Months Ended Redeemable Non- redeemable Redeemable Non- redeemable Basic and diluted net income (loss) per common stock Numerator: Allocation of net loss $ (229,138 ) $ (200,789 ) $ (6,575,981 ) $ (2,341,813 ) Accretion of common stock to redemption value (1) 326,456 — 9,633,966 — Allocation of net income (loss) $ 97,318 $ (200,789 ) $ 3,057,985 $ (2,341,813 ) Denominator: Basic and diluted weighted average shares outstanding 1,852,212 1,623,060 4,557,671 1,623,060 Basic and diluted net income (loss) per common stock $ 0.05 $ (0.12 ) $ 0.67 $ (1.44 ) (1) Accretion amount includes fees deposited into the Trust Account to extend the time for the Company to complete the Business Combination and franchise and income taxes paid out of the Trust Account.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. As of September 30, 2024 and December 31, 2023, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 825, “Financial Instruments,” approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.
Common Stock Subject to Possible Redemption	Common Stock Subject to Possible Redemption The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable common stock (including common stock that feature redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet. The Company has made a policy election in accordance with ASC 480-10-S99-3A and recognizes changes in redemption value in accumulated deficit over an expected 12-month period leading up to a Business Combination. As of September 30, 2024, the Company recorded $326,456 accretion of common stock to redemption value. At September 30, 2024, the amount of common stock subject to possible redemption reflected in the balance sheet are reconciled in the following table: Gross proceeds $ 54,171,800 Less: Proceeds allocated to public rights (6,446,444 ) Allocation of offering costs related to redeemable shares (3,714,253 ) Plus: Accretion of carrying value to redemption value 3,560,360 Common stock subject to possible redemption- December 31, 2022 47,571,463 Plus: Accretion of carrying value to redemption value – for the year ended December 31, 2023 10,332,578 Redeemed common stock payable to public stockholders (25,943,773 ) Common stock subject to possible redemption- December 31, 2023 31,960,268 Plus: Accretion of carrying value to redemption value - nine months ended September 30, 2024 326,456 Redeemed common stock payable to public stockholders (23,176,909 ) Common stock subject to possible redemption- September 30, 2024 $ 9,109,815
Convertible Promissory Note	Convertible Promissory Note The Company elects an early adoption of the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) and accounts for its convertible promissory notes as debt (liability) on the balance sheet. The Company’s assessment of the embedded conversion feature (see Note 5 - Related Party Transactions) considers the derivative scope exception guidance under ASC 815 pertaining to equity classification of contracts in an entity’s own equity. The conversion feature of these promissory notes meets the definition of a derivative instrument. However, bifurcation of conversion feature from the debt host is not required because the conversion feature meets ASC 815 scope exception, as the promissory notes are convertible in shares of the Company’s common stock which is considered indexed to the Company’s own stock and classified in stockholders’ equity.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” (“ASU 2023-09”). This ASU requires that public business entities must annually “(1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income or loss by the applicable statutory income tax rate).” A public entity should apply the amendments in ASU 2023-09 prospectively to all annual periods beginning after December 15, 2024. The Company is currently assessing the impact, if any, that ASU 2023-09 would have on its financial position, results of operations or cash flows. Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
Summary of Significant Accounting Policies (Tables)	Sep. 30, 2024
Summary of Significant Accounting Policies [Abstract]
Schedule of Net Deferred Tax Assets	The Company’s net deferred tax assets are as follows: September 30, December 31, 2024 2023 Deferred tax asset (liability) Startup/Organization Expenses $ 243,409 $ 174,157 Amortization of startup cost (5,069 ) (2,897 ) Unrealized gain on investments held in Trust Account (7,861 ) (29,727 ) Total deferred tax asset (liability) 230,479 141,533 Valuation allowance (230,479 ) 3,147 Deferred tax asset, net of allowance $ — $ 144,680
Schedule of Basic and Diluted Net Income (Loss) Per Common Stock	The net income (loss) per share presented in the statements of operations is based on the following: Three Months Ended Nine Months Ended 2024 2023 2024 2023 Net income (loss) $ (257,656 ) $ 253,265 $ (103,471 ) $ 716,172 Accretion of common stock to redemption value (1) (196,404 ) (675,207 ) (326,456 ) (9,633,966 ) Net loss including accretion of common stock to redemption value $ (454,060 ) $ (421,942 ) $ (429,927 ) $ (8,917,794 ) Three Months Ended Three Months Ended Redeemable Non- redeemable Redeemable Non- redeemable Basic and diluted net income (loss) per common stock Numerator: Allocation of net loss $ (150,583 ) $ (303,477 ) $ (271,532 ) $ (150,410 ) Accretion of common stock to redemption value (1) 196,404 — 675,207 Allocation of net income (loss) $ 45,821 $ (303,477 ) $ 403,675 $ (150,410 ) Denominator: Basic and diluted weighted average shares outstanding 805,352 1,623,060 2,930,090 1,623,060 Basic and diluted net income (loss) per common stock $ 0.06 $ (0.19 ) $ 0.14 $ (0.09 ) Nine Months Ended Nine Months Ended Redeemable Non- redeemable Redeemable Non- redeemable Basic and diluted net income (loss) per common stock Numerator: Allocation of net loss $ (229,138 ) $ (200,789 ) $ (6,575,981 ) $ (2,341,813 ) Accretion of common stock to redemption value (1) 326,456 — 9,633,966 — Allocation of net income (loss) $ 97,318 $ (200,789 ) $ 3,057,985 $ (2,341,813 ) Denominator: Basic and diluted weighted average shares outstanding 1,852,212 1,623,060 4,557,671 1,623,060 Basic and diluted net income (loss) per common stock $ 0.05 $ (0.12 ) $ 0.67 $ (1.44 ) (1) Accretion amount includes fees deposited into the Trust Account to extend the time for the Company to complete the Business Combination and franchise and income taxes paid out of the Trust Account.
Schedule of Common Stock Subject to Possible Redemption	At September 30, 2024, the amount of common stock subject to possible redemption reflected in the balance sheet are reconciled in the following table: Gross proceeds $ 54,171,800 Less: Proceeds allocated to public rights (6,446,444 ) Allocation of offering costs related to redeemable shares (3,714,253 ) Plus: Accretion of carrying value to redemption value 3,560,360 Common stock subject to possible redemption- December 31, 2022 47,571,463 Plus: Accretion of carrying value to redemption value – for the year ended December 31, 2023 10,332,578 Redeemed common stock payable to public stockholders (25,943,773 ) Common stock subject to possible redemption- December 31, 2023 31,960,268 Plus: Accretion of carrying value to redemption value - nine months ended September 30, 2024 326,456 Redeemed common stock payable to public stockholders (23,176,909 ) Common stock subject to possible redemption- September 30, 2024 $ 9,109,815

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
Fair Value Measurements (Tables)	Sep. 30, 2024
Fair Value Measurements [Abstract]
Schedule of Assets that are Measured at Fair Value on a Recurring Basis	The following tables present information about the Company’s assets that are measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023 and indicate the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value. September 30, Quoted Significant Significant Assets Marketable securities held in the Trust Account 9,109,815 9,109,815 — — December 31, Quoted Significant Significant Assets Marketable securities held in the Trust Account 31,960,267 31,960,267 — —

Description of Organization a_2

Description of Organization and Business Operations (Details) - USD ($)				1 Months Ended	9 Months Ended	12 Months Ended
	Oct. 14, 2022	Oct. 06, 2022	Aug. 16, 2022	Oct. 31, 2022	Sep. 30, 2024	Dec. 31, 2023	May 06, 2025	Nov. 30, 2024	Nov. 05, 2024	Oct. 02, 2024	Sep. 04, 2024	Aug. 31, 2024	Aug. 30, 2024	Aug. 06, 2024	Aug. 02, 2024	Jul. 31, 2024	Jul. 08, 2024	Jun. 04, 2024	May 02, 2024	Apr. 30, 2024	Mar. 30, 2024	Jan. 04, 2024	Dec. 29, 2023	Oct. 04, 2023	Jun. 29, 2023	Jun. 28, 2023
Description of Organization and Business Operations [Line Items]
Company incorporated					Mar. 11, 2021
Granted underwriter period					45 days
Term of investment maturity					185 days
Aggregate fair market value, percentage					80%
Agreement percentage					80%
Trust account balance, percentage					80%
Company’s obligation percentage					100%
Amount deposited in trust account					$ 20,000								$ 20,000		$ 20,000											$ 70,000
Current equity value					1,000,000,000
Aggregate shares					$ 2,487,090
Common stock redemption price per share (in Dollars per share)					$ 0.0001	$ 0.0001
Loan amount																	$ 20,000	$ 20,000	$ 20,000	$ 70,000	$ 200,000	$ 200,000
Unsecured promissory note					$ 300,000				$ 20,000	$ 20,000							20,000	20,000	20,000
Aggregate shares redemption (in Shares)					2,124,738
Redemption value					$ 23,176,909
Redemption price per share (in Dollars per share)					$ 10.91
Interest to pay dissolution expenses)					$ 50,000
Per share value of assets (in Dollars per share)					$ 10.15
Public share (in Dollars per share)					$ 10.15
Cash					$ 109,650	$ 339
Working capital deficit					2,431,129
Payment from the sponsor					25,000
Repayment of promissory notes				$ 300,000
Sponsor provided loan						449,780
Outstanding balance						97,052
Transaction cost						100,000
U.S. federal excise tax			1%
Excise tax			1%
Excise tax liability					231,769	$ 259,438
Outstanding excise tax liability					491,207
Bestpath [Member]
Description of Organization and Business Operations [Line Items]
Deposits					$ 490,000																		$ 70,000	$ 210,000	$ 210,000
Unsecured promissory note											$ 20,000			$ 20,000		$ 20,000				70,000
Huture [Member]
Description of Organization and Business Operations [Line Items]
Loan amount												$ 20,000
Business Combination [Member]
Description of Organization and Business Operations [Line Items]
Shares price per unit (in Dollars per share)					$ 10.15
Acquires percentage of outstanding voting secuities					50%
Business Combination [Member]
Description of Organization and Business Operations [Line Items]
Amount deposited in trust account					$ 490,000																		$ 70,000	$ 210,000	$ 210,000
Common stock redemption price per share (in Dollars per share)					$ 10.43
Loan amount																	$ 20,000	$ 20,000	$ 20,000	$ 70,000
Sponsor [Member]
Description of Organization and Business Operations [Line Items]
Shares price per unit (in Dollars per share)					$ 0.15
Amount deposited in trust account					$ 750,000
Aggregate public share					1,500,000
Related Party [Member] \| Business Combination [Member]
Description of Organization and Business Operations [Line Items]
Conversion amount					$ 99,846
PubCo Ordinary Share [Member]
Description of Organization and Business Operations [Line Items]
Shares price per unit (in Dollars per share)					$ 10
Common Stock [Member]
Description of Organization and Business Operations [Line Items]
Shares price per unit (in Dollars per share)					$ 8.33
Redemption value					$ 25,943,773
Forecast [Member]
Description of Organization and Business Operations [Line Items]
Amount deposited in trust account							$ 20,000
Forecast [Member] \| Huture [Member]
Description of Organization and Business Operations [Line Items]
Loan amount								$ 20,000
IPO [Member]
Description of Organization and Business Operations [Line Items]
Units issued during period shares new issues (in Shares)		5,000,000
Shares price per unit (in Dollars per share)		$ 10
Generating gross proceeds		$ 50,000,000
Granted underwriter period		45 days
Private Placement [Member]
Description of Organization and Business Operations [Line Items]
Private units generating gross proceeds	$ 125,154	$ 2,562,500
Additional units issued (in Shares)	12,515.4
Private Placement [Member] \| Sponsor [Member]
Description of Organization and Business Operations [Line Items]
Units issued during period shares new issues (in Shares)		256,250
Shares price per unit (in Dollars per share)		$ 10
Sale of unit (in Shares)		256,250
Private Placement [Member] \| Related Party [Member]
Description of Organization and Business Operations [Line Items]
Per unit (in Dollars per share)		$ 10
Over-Allotment Option [Member]
Description of Organization and Business Operations [Line Items]
Units issued during period shares new issues (in Shares)	417,180
Shares price per unit (in Dollars per share)	$ 10
Generating gross proceeds	$ 4,171,800
Per unit (in Dollars per share)	$ 10
Granted underwriter period					45 days
Additional units issued (in Shares)		750,000			750,000
Gross proceeds over-allotment option units	$ 4,171,800
Trust Account [Member]
Description of Organization and Business Operations [Line Items]
Generating gross proceeds					$ 54,984,377

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Summary of Significant Accounting Policies [Abstract]
Cash	$ 109,650		$ 109,650		$ 339
Cash equivalents
Trust account	$ 9,109,815		9,109,815		$ 31,960,267
Interests earned from the Trust Account			$ 789,549	$ 1,703,374
Effective tax rate percent	(9.62%)	26.09%	146.54%	24.66%
Statutory tax rate	21%	21%	21%	21%
Change in valuation allowance	$ 28,258		$ 233,626
Federal depository insurance coverage			250,000
Common stock to redemption value			$ 326,456

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of Net Deferred Tax Assets - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Schedule of Net Deferred Tax Assets [Abstract]
Startup/Organization Expenses	$ 243,409	$ 174,157
Amortization of startup cost	(5,069)	(2,897)
Unrealized gain on investments held in Trust Account	(7,861)	(29,727)
Total deferred tax asset (liability)	230,479	141,533
Valuation allowance	(230,479)	3,147
Deferred tax asset, net of allowance		$ 144,680

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details) - Schedule of Basic and Diluted Net Income (Loss) Per Common Stock - USD ($)		3 Months Ended						9 Months Ended
		Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Schedule of Basic and Diluted Net Income (Loss) Per Common Stock [Line Items]
Net income (loss)		$ (257,656)	$ 55,371	$ 98,814	$ 253,265	$ 311,101	$ 151,806	$ (103,471)	$ 716,172
Accretion of common stock to redemption value	[1]	(196,404)			(675,207)			(326,456)	(9,633,966)
Net loss including accretion of common stock to redemption value		(454,060)			(421,942)			(429,927)	(8,917,794)
Redeemable Shares [Member]
Schedule of Basic and Diluted Net Income (Loss) Per Common Stock [Line Items]
Accretion of common stock to redemption value	[1]	196,404			675,207			326,456	9,633,966
Basic and diluted net income (loss) per common stock
Allocation of net loss		(150,583)			(271,532)			(229,138)	(6,575,981)
Allocation of net income (loss)		$ 45,821			$ 403,675			$ 97,318	$ 3,057,985
Denominator:
Basic and diluted weighted average shares outstanding (in Shares)		805,352			2,930,090			1,852,212	4,557,671
Diluted weighted average shares outstanding (in Shares)		805,352			2,930,090			1,852,212	4,557,671
Basic and diluted net income (loss) per common stock (in Dollars per share)		$ 0.06			$ 0.14			$ 0.05	$ 0.67
Diluted net income (loss) per common stock (in Dollars per share)		$ 0.06			$ 0.14			$ 0.05	$ 0.67
Numerator:
Allocation of net loss		$ (150,583)			$ (271,532)			$ (229,138)	$ (6,575,981)
Allocation of net income (loss)		45,821			403,675			97,318	3,057,985
Non- Redeemable Shares [Member]
Schedule of Basic and Diluted Net Income (Loss) Per Common Stock [Line Items]
Accretion of common stock to redemption value	[1]
Basic and diluted net income (loss) per common stock
Allocation of net loss		(303,477)			(150,410)			(200,789)	(2,341,813)
Allocation of net income (loss)		$ (303,477)			$ (150,410)			$ (200,789)	$ (2,341,813)
Denominator:
Basic and diluted weighted average shares outstanding (in Shares)		1,623,060			1,623,060			1,623,060	1,623,060
Diluted weighted average shares outstanding (in Shares)		1,623,060			1,623,060			1,623,060	1,623,060
Basic and diluted net income (loss) per common stock (in Dollars per share)		$ (0.19)			$ (0.09)			$ (0.12)	$ (1.44)
Diluted net income (loss) per common stock (in Dollars per share)		$ (0.19)			$ (0.09)			$ (0.12)	$ (1.44)
Numerator:
Allocation of net loss		$ (303,477)			$ (150,410)			$ (200,789)	$ (2,341,813)
Allocation of net income (loss)		$ (303,477)			$ (150,410)			$ (200,789)	$ (2,341,813)

[1] Accretion amount includes fees deposited into the Trust Account to extend the time for the Company to complete the Business Combination and franchise and income taxes paid out of the Trust Account.

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details) - Schedule of Common Stock Subject to Possible Redemption - Common Stock Subject to Possible Redemption [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Common Stock Subject To Possible Redemption [Line Items]
Gross proceeds			$ 54,171,800
Less:
Proceeds allocated to public rights			(6,446,444)
Allocation of offering costs related to redeemable shares			(3,714,253)
Plus:
Accretion of carrying value to redemption value	$ 326,456	$ 10,332,578	3,560,360
Redeemed common stock payable to public stockholders	(23,176,909)	(25,943,773)
Common stock subject to possible redemption	$ 9,109,815	$ 31,960,268	$ 47,571,463

Initial Public Offering (Detail

Initial Public Offering (Details) - USD ($)			9 Months Ended
Initial Public Offering (Details) - USD ($)	Oct. 14, 2022	Oct. 06, 2022	Sep. 30, 2024
IPO [Member]
Class of Stock [Line Items]
Sale of units		5,000,000
Unit price (in Dollars per share)		$ 10
Gross proceeds (in Dollars)		$ 50,000,000
Granted underwriters period		45 days
Sale of stock description			Each Unit consists of one share of common stock and one right (“Public Right”). Each Public Right will convert into one-fifth (1/5) of one share of common stock upon the consummation of a Business Combination.
Over-Allotment Option [Member]
Class of Stock [Line Items]
Sale of units	417,180
Unit price (in Dollars per share)	$ 10
Gross proceeds (in Dollars)	$ 4,171,800
Granted underwriters period			45 days
Purchase of additional units		750,000	750,000
Price per unit (in Dollars per share)	$ 10
Public shares			5,417,180

Private Placement (Details)

Private Placement (Details) - USD ($)	Oct. 14, 2022	Oct. 06, 2022	Sep. 30, 2024
Private Placement [Member]
Private Placement [Line Items]
Generating gross proceeds (in Dollars)	$ 125,154	$ 2,562,500
Sale of stock description		Each Private Unit will consist of one share of common stock (“Private Share”) and one right (“Private Right”).
Converted common shares	1
Private Placement [Member] \| Sponsor [Member]
Private Placement [Line Items]
Number of private units		256,250
Price per unit (in Dollars per share)		$ 10
Over-Allotment Option [Member]
Private Placement [Line Items]
Number of private units	417,180
Price per unit (in Dollars per share)	$ 10
Number of additional units purchased	12,515.4		750,000

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)

9 Months Ended

12 Months Ended

Jan. 04, 2024

Dec. 29, 2023

Jun. 26, 2023

Oct. 14, 2022

Apr. 01, 2021

Sep. 30, 2024

Sep. 30, 2023

Dec. 31, 2023

Nov. 05, 2024

Oct. 02, 2024

Aug. 30, 2024

Aug. 02, 2024

Jul. 08, 2024

Jun. 04, 2024

May 02, 2024

Apr. 30, 2024

Apr. 08, 2024

Mar. 30, 2024

Mar. 01, 2024

Feb. 02, 2024

Oct. 03, 2023

Jun. 29, 2023

Jun. 28, 2023

Mar. 31, 2023

Feb. 23, 2023

Feb. 08, 2023

Related Party Transactions [Line Items]

Aggregate price

$ 25,000

Initial stockholders percentage

20%

Subject to certain limited exceptions percentage

50%

Trading days

20 days

Trading day period commencing business combination

30 days

Loan amount

$ 200,000

$ 20,000

$ 70,000

$ 200,000

Outstanding balance

97,052

$ 99,846

$ 97,052

Promissory Notes

300,000

$ 20,000

Due to related party

138,665

$ 97,052

Advance amount

202,948

$ 370,000

Outstanding amount

760,000

490,000

Deposited into trust account

$ 20,000

$ 70,000

Promissory Note 4 [Member]

Related Party Transactions [Line Items]

Outstanding balance

99,846

Promissory Note [Member]

Related Party Transactions [Line Items]

Promissory Notes

$ 70,000

Advance amount

$ 70,000

Sponsor [Member]

Related Party Transactions [Line Items]

Price per unit (in Dollars per share)

$ 10

Aggregate principal amount

$ 200,000

Common stock per share (in Dollars per share)

$ 0.15

Deposited into trust account

$ 750,000

Related Party [Member] | Promissory Note [Member]

Related Party Transactions [Line Items]

Promissory Notes

$ 849,626

549,626

Bestpath [Member]

Related Party Transactions [Line Items]

Common stock per share (in Dollars per share)

$ 8.33

Loan amount

$ 210,000

Huture [Member]

Related Party Transactions [Line Items]

Common stock per share (in Dollars per share)

$ 8.33

Promissory Notes

$ 20,000

Outstanding amount

$ 40,000

$ 0

Insider Shares [Member]

Related Party Transactions [Line Items]

Subject to certain limited exceptions percentage

50%

Line of Credit [Member] | Promissory Note 1 [Member]

Related Party Transactions [Line Items]

Loan amount

$ 100,000

Line of Credit [Member] | Promissory Note 2 [Member]

Related Party Transactions [Line Items]

Loan amount

$ 140,000

Line of Credit [Member] | Promissory Note 3 [Member]

Related Party Transactions [Line Items]

Loan amount

$ 130,000

Line of Credit [Member] | Promissory Note 4 [Member]

Related Party Transactions [Line Items]

Loan amount

$ 179,626

Line of Credit [Member] | Sponsor [Member] | Promissory Note 5 [Member]

Related Party Transactions [Line Items]

Transaction costs related to business combination

$ 100,000

Common Stock [Member]

Related Party Transactions [Line Items]

Shares issued (in Shares)

1,437,500

Common stock exceed price (in Dollars per share)

$ 12.5

Common stock per share (in Dollars per share)

$ 8.33

Over-Allotment Option [Member]

Related Party Transactions [Line Items]

Shares subject to forfeiture (in Shares)

83,205

Common stock per share (in Dollars per share)

$ 10

Over-Allotment Option [Member] | Common Stock [Member]

Related Party Transactions [Line Items]

Shares subject to forfeiture (in Shares)

187,500

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)			9 Months Ended
Commitments and Contingencies (Details) - USD ($)	Oct. 14, 2022	Oct. 06, 2022	Sep. 30, 2024
Commitments and Contingencies [Line Items]
Granted underwriters option period			45 days
Underwriter cash discount			$ 812,577
deferred fee percentage			3.50%
Deferred underwriting commissions payable			$ 1,896,013
Sold amount		$ 100
Over-Allotment Option [Member]
Commitments and Contingencies [Line Items]
Granted underwriters option period			45 days
Additional units purchase	12,515.4		750,000
Common stock price per share	$ 10
Number of units	417,180
Price per share	$ 10
IPO [Member]
Commitments and Contingencies [Line Items]
Granted underwriters option period		45 days
Underwriting discount gross proceeds percentage			0.75%
Common stock price per share		$ 10
Number of units		5,000,000
IPO [Member] \| Common Stock [Member]
Commitments and Contingencies [Line Items]
Common stock price per share			$ 10
Private Units [Member]
Commitments and Contingencies [Line Items]
Number of units			50,000
Unit Purchase Option [Member]
Commitments and Contingencies [Line Items]
Number of units		97,509
Price per share		$ 11.5
Weighted average trading price		115%

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Common Stock [Member] - $ / shares			9 Months Ended	12 Months Ended
	Oct. 14, 2022	Dec. 31, 2021	Sep. 30, 2024	Dec. 31, 2021	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022
Stockholders’ Equity [Line Items]
Common stock, shares authorized			10,000,000
Common stock, par value (in Dollars per share)			$ 0.0001
Common stock voting rights			one
Common stock, shares issued			1,623,060				1,623,060
Common stock, shares outstanding			1,623,060		1,623,060	1,623,060	1,623,060	1,623,060	1,623,060	1,623,060	1,623,060
Shares subject to forfeiture				187,500
Percentage of initial stockholders		20%
Common stock shares	187,500
Common stock, subject to possible redemption			805,352				2,930,090
Over-Allotment Option [Member]
Stockholders’ Equity [Line Items]
Common stock, shares issued		1,437,500		1,437,500
Common stock, shares outstanding		1,437,500		1,437,500
Common stock shares	104,295

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Schedule of Assets that are Measured at Fair Value on a Recurring Basis - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Assets
Marketable securities held in the Trust Account	$ 9,109,815	$ 31,960,267
Quoted Prices in Active Markets (Level 1)
Assets
Marketable securities held in the Trust Account	9,109,815	31,960,267
Significant Other Observable Inputs (Level 2)
Assets
Marketable securities held in the Trust Account
Significant Other Unobservable Inputs (Level 3)
Assets
Marketable securities held in the Trust Account

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member]	Nov. 05, 2024 USD ($) $ / shares
Unsecured Promissory Note [Member]
Subsequent Events [Line Items]
Unsecured promissory note \| $	$ 20,000
Common Stock [Member]
Subsequent Events [Line Items]
Common stock price per share \| $ / shares	$ 8.33